Vijaya Diagnostic Reports Strong Q4 FY26 Results: Revenue Up 26.6%, Margins at 43.5%

Vijaya Diagnostic Centre Ltd announced robust financial results for the fourth quarter and full fiscal year ended March 31, 2026. The company reported a 26.6% year-on-year increase in consolidated revenue from operations for Q4 FY26, reaching ₹219.38 crore. For the full fiscal year FY26, revenue grew 19.5% to ₹814.20 crore, and Profit After Tax (PAT) rose 20.3% to ₹172.98 crore.

Financial Performance Highlights

EBITDA margins showed significant improvement. In Q4 FY26, margins stood at a strong 43.5%, up 379 basis points from 39.8% in the year-ago period. For the full fiscal year FY26, margins improved to 41.4% from 40.1% in FY25.

Strategic Growth and Operational Efficiency

This performance highlights healthy demand for diagnostic services and successful network expansion. Improved EBITDA margins point to operational efficiencies and effective cost management, boosting profitability. Vijaya Diagnostic is pursuing growth by expanding its network of diagnostic hubs and spokes across South India, with a strategy to quickly achieve operational break-evens for new units. The company also invests in technology, including AI-led solutions, to enhance diagnostic accuracy and workflow optimization.

Future Expansion and New Services

Looking ahead to FY27, the company plans to add 4-5 new hubs and 10-12 spokes to its network. It will also introduce advanced genomic testing capabilities to diversify its service offerings into specialized diagnostics. Continued deployment of AI solutions is expected to drive further efficiencies and improve diagnostic accuracy, while newer facilities are achieving break-even faster, contributing positively to overall profitability.

Potential Risks to Monitor

The company's forward-looking statements are subject to risks and uncertainties. These could include significant changes in the economic environment, tax laws, import duties, litigation, and labor relations, which might affect future performance.

Peer Landscape

Other key diagnostic players like Dr. Lal PathLabs and Metropolis Healthcare are also expanding networks and integrating new technologies. The sector trend indicates growth driven by increased health awareness and a focus on specialized diagnostics.

What to Track Next

Investors will be watching the successful launch and performance of the planned new hubs and spokes for FY27. Market adoption and revenue from the advanced genomic testing capabilities will also be key. Continued impact of AI solutions on efficiency and accuracy, and the break-even timelines for recent openings, will be important indicators.